Nutra Pharma To Present at Upcoming Investment Conference
September 09, 2015 Nutra Pharma is announcing that they will present at the upcoming See Thru Equities Conference in New York City on Thursday, September 10, 2015. September 9, 2015 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyelo
Nutra Pharma's RPI-78M Granted Orphan Drug Status by the US Food and Drug Administration for the
September 08, 2015 September 8, 2015 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTC: NPHC), announced today that they have received Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Multiple Sclerosis in children. “Receiving Orphan Drug Designation by the FDA is a significant milestone for our Company,” stated Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “Juvenile MS is an important disease area t
